Twinter, Ken, Misiu--Appreciate the back and forth on the

New Post Public Reply Private Reply Replies (1) Message Board
sherlock57 twinter11 #159454
643
Twinter, Ken, Misiu--Appreciate the back and forth on the trial and how we might expect things to turn out. I do believe there is one variable at play that might influence results in the 350mg arm of the trial that hasn't been discussed. And that is the possible influence of mRNA vaccines on PDL-1 expression. To whit:

"Research indicates mRNA vaccines act as potent immune modulators, stimulating a surge in type1 interferon that primes the system to better recognize and attack tumor cells, especially in "immune-cold" tumors that usually don't respond well to ICIs." (The quote is from google ai, and lines up with the details in the Grippen article in the Oct 2025 issue of Nature. Grippen's study suggested a doubling of overall survival in NSCLC and melanoma, so the influence is significant... if the retrospective study holds up.)

Will 350mg of leronlimab PLUS an mRNA vaccine boost PDL-1 levels enough to qualify for an ICI? That is one of the questions this trial will answer, whether or not we asked it... or wanted to! And the answer might confuse things a bit. This is where all the documentation that Creatv Bio is doing will allow Cytodyn to track the biomarkers and parse out the individual contributions of each therapeutic. At least I hope so.

Personally, I am "holding out hope for those first few" because the combination of 350mg and an mRNA vaccine has never been specifically studied before, at least prospectively, in cancer. Who knows, the mRNA vaccine may have influenced the MASH trial results, which, as you recall, showed surprisingly effective results at the 350mg dose. (And that is rank speculation on my part... an alternative explanation to Ohms thoughts).

In terms of cancer therapeutics, I think we are in a post-mRNA world, so to speak. Basically, all the ICI trials since the mRNA vaccines need to be re-evaluated... (Or, they should be. And yet we haven't heard anything about this from the FDA or NIH. Which leaves me thinking--what the hell are they thinking?). And not a word from all the ICI manufacturers, whom I suspect aren't keen on dealing with these implications. And who knows, apparently the mRNA vaccine may help chemo work better, too. Could that be a reason I am cancer-free for 3.5 years after surgery, oxaliplatin and capecitabine, for locally advanced mss CRC? If I was an unknowing guinea pig... well, science works in mysterious ways.

It strikes me that the two most important therapeutic advances in cancer in the last couple years--boosting PDL-1 by leronlimab and the mRNA vaccines--were both accidents, essentially. That is one reason why I think AI might not be such a big deal in medicine--it can't replicate the plodding, mistake-filled process of science as a human endeavor. Where so many breakthroughs come from accidental observations, like most famously penicillin, but also x-rays, warafin, quinine, and the link between the pancreas and blood sugar levels/diabetes. But I digress...

The money question--will patients taking mRNA vaccines screw up the mCRC trial with leronlimab? Well, it will potentially help the PFS and OS numbers in the 700mg cohort, whether or not they receive an ICI. So no problem there. And it might help those in the 350mg cohort survive long enough to benefit from an ICI. Which will confuse the dosing issue. But if the results in the 700mg cohort are close to the numbers that have gotten us all excited--60% ORR in mCRC, without an ICI... 5 out of 5 alive after 5 years when paired with an ICI in mTNBC--then the influence of the mRNA vaccine will be seen for what it is--background noise, likely with a small, additive benefit. If it turns out the mRNA vaccines, paired with leronlimab, do provide a substantial benefit... well, leronlimab is still a huge part of the solution. Let's say it's the combination of mRNA vax and leronlimab that controls metastasis... it still means leronlimab has a crucial place in cancer treatment.

This is all educated speculation... because the efficacy of both leronlimab and mRNA vax in cancer treatment has been prospectively proved. We don't even know if or how the mRNA vaccines helped out our Ladies, in fact. I'm hopeful we'll get some complete responses in the 700mg arm--without an ICI. That would prove the efficacy of leronlimab added to SOC in mCRC, and establish an MOA independent of ICIs (by controlling metastasis). Further on down the line, they may very well need an ICI if they progress. Either way, leronlimab saves lives. And the documentation of all these biomarkers in the trial will provide the "unassailable evidence" we need to revolutionize cancer treatment in our time.

Look, I'm a carpenter and documentary artist, with absolutely no background in the hard sciences. My last lab class in biology was way back in high school! I do read quite a bit about leronlimab and CCR5 and biotech, though... but it is book knowledge, and my comments/conclusions may be off-base. So Kat, Ohm, Plot et al--and anyone with a medical background--please weigh in here. Especially on the implications of the mRNA vaccines on contemporary clinical trials in cancer. And, if you had cancer and didn't have access to leronlimab--would you take an mRNA vaccine along with an ICI, if it was prescribed... based on what you know from the Nature article?

Thanks again to Twinter, Ken and Misiu for getting the dialogue going and for interesting posts. And--would you all seek out an mRNA vax if you were getting an ICI for cancer?

Sherlock57 (from a cold, overcast, sad Minneapolis)





CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 534

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 98

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 445

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 191

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 303

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 410

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
AutoShop Answers Extends 2027 Training Into Fridays

Updated Category News Views 55

A repair bay can hum all day while the back office quietly bleeds profit. That unglamorous reality is why AutoShop Answers adding nine Friday specialty classes to its 2027 Key2Key Weekend calendar deserves a closer look. This is not a new tool chest or some vague motivational roadshow; it is an attempt to give independent shop owners an extra day to work on the pieces...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 137

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 666

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading

Top 5 Most Recently Viewed Articles

Regulatory T-Cells Market Growth Driven by New Therapies

Updated Category News Views 217

Insights into the Regulatory T-Cells Market Growth The landscape of the Treg therapy market is rapidly evolving as companies globally actively develop innovative regulatory T-cell therapies to treat various critical conditions. These include systemic lupus erythematosus (SLE), lupus nephritis, atopic dermatitis, rheumatoid arthritis, psoriasis, progressive multiple...

Continue Reading
Natural Grocers Unveils Autumnfest Super Savings Event

Updated Category News Views 67

Natural Grocers Introduces Autumnfest Savings Event As the autumn leaves begin to fall, Natural Grocers invites shoppers to revel in the festivities of the season with their exciting Autumnfest Savings Event. This annual celebration promises customers an incredible opportunity to enjoy significant discounts, free samples, and delightful seasonal recipes. With savings of...

Continue Reading
Anthem Blue Cross Commits $10 Million for Wildfire Relief

Updated Category News Views 270

Anthem Blue Cross Generously Assists Communities Affected by Wildfires For over eight decades, Anthem Blue Cross has maintained a strong presence in California, prioritizing the health and well-being of its residents. Our focus has always been on putting people first, as we acknowledge the struggles that come with disasters that can significantly impact the lives of our...

Continue Reading
Corporate Legal Departments Face Major Workforce Challenges

Updated Category News Views 179

Corporate Legal Departments Face Major Workforce Challenges In the evolving landscape of corporate legal departments, a significant wave of attrition is looming as in-house attorneys express a desire to seek better opportunities. The increase in workloads, coupled with concerns about artificial intelligence and limited career advancement prospects, has prompted many legal...

Continue Reading
Currax Achieves FDA Approval for Enhanced CONTRAVE Supply Chain

Updated Category News Views 411

Currax Expands Manufacturing Capabilities for CONTRAVE Currax Pharmaceuticals LLC, a focused specialty pharmaceutical company, recently announced a significant milestone in its operations. The U.S. Food and Drug Administration (FDA) has granted approval for a second manufacturing facility dedicated to the production of CONTRAVE (naltrexone HCl/bupropion HCl), a leading...

Continue Reading